You just read:

DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)

News provided by

DelMar Pharmaceuticals, Inc.

Aug 13, 2019, 09:00 ET